EP2786140A4 - PACLITAXEL RESPONSE MARKERS FOR CANCER - Google Patents

PACLITAXEL RESPONSE MARKERS FOR CANCER

Info

Publication number
EP2786140A4
EP2786140A4 EP12852702.5A EP12852702A EP2786140A4 EP 2786140 A4 EP2786140 A4 EP 2786140A4 EP 12852702 A EP12852702 A EP 12852702A EP 2786140 A4 EP2786140 A4 EP 2786140A4
Authority
EP
European Patent Office
Prior art keywords
cancer
response markers
paclitaxel response
paclitaxel
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12852702.5A
Other languages
German (de)
French (fr)
Other versions
EP2786140A1 (en
Inventor
Edwin Wang
Jie Li
Maureen O'connor-Mccourt
Enrico Purisima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of EP2786140A1 publication Critical patent/EP2786140A1/en
Publication of EP2786140A4 publication Critical patent/EP2786140A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP12852702.5A 2011-11-28 2012-11-27 PACLITAXEL RESPONSE MARKERS FOR CANCER Withdrawn EP2786140A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563929P 2011-11-28 2011-11-28
PCT/CA2012/001087 WO2013078537A1 (en) 2011-11-28 2012-11-27 Paclitaxel response markers for cancer

Publications (2)

Publication Number Publication Date
EP2786140A1 EP2786140A1 (en) 2014-10-08
EP2786140A4 true EP2786140A4 (en) 2015-10-28

Family

ID=48534552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12852702.5A Withdrawn EP2786140A4 (en) 2011-11-28 2012-11-27 PACLITAXEL RESPONSE MARKERS FOR CANCER

Country Status (8)

Country Link
US (1) US20140349878A1 (en)
EP (1) EP2786140A4 (en)
JP (1) JP2014533955A (en)
CN (1) CN104024851A (en)
AU (1) AU2012344676A1 (en)
CA (1) CA2857191A1 (en)
HK (1) HK1201583A1 (en)
WO (1) WO2013078537A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525382T3 (en) 2010-03-31 2014-12-23 Sividon Diagnostics Gmbh Method for predicting breast cancer recurrence under endocrine treatment
US20150376714A1 (en) * 2013-02-01 2015-12-31 Sividon Diagnostics Gmbh Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
EP3063689A4 (en) * 2013-10-29 2017-08-30 Genomic Health, Inc. Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk
EP3158087A4 (en) * 2014-06-19 2018-03-21 Hidenseq Polymorphism in the bcl2 gene determines response to chemotherapy
MX383691B (en) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc TREATMENT METHOD FOR CANCER ASSOCIATED WITH A RAS MUTATION.
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (en) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Method for reducing neutropenia
JP2020503363A (en) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド Tubulin binding compounds and their therapeutic use
BR112019015974A2 (en) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. METHOD TO REDUCE NEUTROPENY
CN107083423B (en) * 2017-03-27 2022-01-28 北京极客基因科技有限公司 Drug target prediction and drug full-range evaluation method
EP3679160A4 (en) 2017-09-08 2021-05-19 Myriad Genetics, Inc. METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES TO PREDICT THE INTEREST OF CHEMOTHERAPY
KR20200112881A (en) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. Composition and method for reducing thrombocytopenia through administration of plinabulin
MX2021005646A (en) * 2018-11-14 2021-08-11 Beyondspring Pharmaceuticals Inc Methods of treating cancer using tubulin binding agents.
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113355419B (en) * 2021-06-28 2022-02-18 广州中医药大学(广州中医药研究院) Breast cancer prognosis risk prediction marker composition and application
CN116411072B (en) * 2022-12-28 2023-09-19 北京大学第一医院 A combination of markers for diagnosis and treatment of acral melanoma and its application
CN118486374B (en) * 2024-05-29 2025-05-06 高精(浙江安吉)精准医学科技有限公司 Tumor cell identification method based on single-cell sequencing data

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062811A2 (en) * 2004-12-08 2006-06-15 Aventis Pharmaceuticals Inc. Method for measuring resistance or sensitivity to docetaxel
WO2008006517A2 (en) * 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054814A1 (en) * 2003-11-26 2005-06-16 Yale University Apoptosis-based evaluation of chemosensitivity in cancer patients
JP5020088B2 (en) * 2004-11-05 2012-09-05 ジェノミック ヘルス, インコーポレイテッド Predicting response to chemotherapy using gene expression markers
CN101365806B (en) * 2005-12-01 2016-11-16 医学预后研究所 Methods and devices for identifying biomarkers of therapeutic response and use thereof for predicting therapeutic effect
CN101424638A (en) * 2006-09-27 2009-05-06 广东省人民医院 Paclitaxel drug curative effect prediction kit and its application
DK2297359T3 (en) * 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
WO2010147961A1 (en) * 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
US9771618B2 (en) * 2009-08-19 2017-09-26 Bioarray Genetics, Inc. Methods for treating breast cancer
JPWO2011065533A1 (en) * 2009-11-30 2013-04-18 国立大学法人大阪大学 How to determine sensitivity to breast cancer preoperative chemotherapy
ES2364166B1 (en) * 2009-12-31 2012-07-10 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) GENOMIC FOOTPRINT AS A PREDICTOR OF TREATMENT RESPONSE.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062811A2 (en) * 2004-12-08 2006-06-15 Aventis Pharmaceuticals Inc. Method for measuring resistance or sensitivity to docetaxel
WO2008006517A2 (en) * 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Affymetrix GeneChip Human Genome U133 Array Set HG-U133A", GEO, 11 March 2002 (2002-03-11), pages 1 - 4, XP002254749 *
IWAO-KOIZUMI K ET AL: "PREDICTION OF DOCETAXEL RESPONSE IN HUMAN BREAST CANCER BY GENE EXPRESSION PROFILING", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 23, no. 3, 20 January 2005 (2005-01-20), pages 422 - 431, XP009058742, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.09.078 *
See also references of WO2013078537A1 *

Also Published As

Publication number Publication date
CN104024851A (en) 2014-09-03
US20140349878A1 (en) 2014-11-27
CA2857191A1 (en) 2013-06-06
EP2786140A1 (en) 2014-10-08
HK1201583A1 (en) 2015-09-04
WO2013078537A1 (en) 2013-06-06
JP2014533955A (en) 2014-12-18
AU2012344676A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
EP2786140A4 (en) PACLITAXEL RESPONSE MARKERS FOR CANCER
CY2024011I2 (en) ANTI-FCRN ANTIBODIES
HUS2300021I1 (en) Anti-IL-36R antibodies
CY2019017I1 (en) CGRP ANTIBODIES
EP2931922A4 (en) CUSTOM BIOMARKERS FOR CANCER
EP2750596A4 (en) INTEGRATED ARCHITECTURES FOR INTEGRATED SYSTEM
EP2718836A4 (en) DISCOUNT REDIRECTIONS
EP2828405A4 (en) PANEL OF MARKERS FOR THE DETECTION OF CANCER
EP2834700A4 (en) PROXIMITY DETECTION FOR FLASH DETECTION
PL2906251T3 (en) Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
EP2751387A4 (en) SELF-SUSPENDED RETAINING AGENTS FOR HYDRAULIC FRACTURING
EP2708280A4 (en) MICRORACTOR FOR PHOTORACTIONS
CO6801637A2 (en) Antibody formulations
EP2847592A4 (en) FUNCTIONAL SUBSTITUTE DIAGNOSTIC ASSAY FOR CANCER
EP2548549A4 (en) COMPOSITION FOR EMULSION
EP2920368A4 (en) VEHICLE FOR GROUND MARKING
BR112014025037A2 (en) Anti-FGFR2 antibody
BR112013030212A2 (en) hydraulic deaerator
EP2847355A4 (en) GENETIC DIAGNOSTIC MARKER GROUP FOR COLORECTAL CANCER
DK2917244T3 (en) APROTININ-DERIVED POLYPEPTIDE-ANTIBODY CONJUGATES
EP2780480A4 (en) GAMMA-PNA MINISONDES FOR FLUORESCENT MARKING
EP2686447A4 (en) PROSTATE CANCER PROGNOSTIC MARKER SETS
DK3521315T3 (en) Anti-transglutaminase-2 antibodies
DK2828292T3 (en) JCV-NEUTRALIZING ANTIBODIES
EP2699237A4 (en) THERAPY FOR LEUKEMIA

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101AFI20150605BHEP

Ipc: G01N 33/48 20060101ALI20150605BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150928

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101AFI20150922BHEP

Ipc: G01N 33/48 20060101ALI20150922BHEP

17Q First examination report despatched

Effective date: 20160527

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161207